The Organ-on-a-Chip Company
Complex tissues, surprisingly simple
Our vision is to create the simplest device for the most complex 3D biology. With perfused vessels, co-cultures and optimized microenvironments. And so easy-to-use that you almost forget you’re working with probably the most advanced tissue culture platform ever. With the OrganoPlate®, that vision is now here. Say hello to the OrganoPlate®, the future of 3D tissue models.
We all want better medicines, that’s obvious. To make this possible, we need better disease models, fully human and physiologically relevant. Truly informative tools, compatible with compounds and with high-throughput readout equipment. And of course we need them today, rather than tomorrow. As true pioneers in organ-on-a-chip biology, we are proud to develop any-throughput human tissue and disease models in the OrganoPlate® for the industry.
Company structure and locations
MIMETAS B.V. is a privately-owned biotech company, based in Leiden (NL). MIMETAS was incorporated in 2013 and has currently three offices, with its headquarters located in Leiden. In Leiden we perform most of the biological model development work, as well as development of novel hardware and assays. Our manufacturing site is located in Enschede, in the eastern part of The Netherlands. Here we produce OrganoPlates® under strictly controlled cleanroom conditions. In Gaithersburg (MD) in the USA, and In Tokyo, Japan, we have subsidiaries involved in selected R&D, customer support and business development.
MIMETAS works as a highly motivated team, collaborating with the majority of the top pharmaceutical companies and top scientists. MIMETAS develops organ-on-a-chip models to specification in OrganoPlates®, markets OrganoPlates® and performs self-funded R&D on groundbreaking organ-on-a-chip models.
A short history
In 2010, Paul Vulto met Jos Joore for dinner in a Japanese restaurant in Rotterdam. Paul showed the PhaseGuide™ technology that he had invented in Germany and Italy. Jos Joore, who was into diagnostic array technology and protein profiling at the time, was immediately intrigued. Together they brainstormed on creating the phenotypic equivalent of a microarray that could be used for massive parallel testing of individualized (combination) therapies. That same evening Paul called Prof. Thomas Hankemeier from Leiden University to discuss the possibilities of starting up a science-based business. This was the start of MIMETAS. In 2013, MIMETAS was incorporated and acquired its first commercial project on organ-on-a-chip development.
High-tech industrial production facility
We produce our OrganoPlates® in our production facilities at the High Tech Factory in Enschede (NL). In this manufacturing site, state-of-the-art equipment enables automated and fully scalable production of 250.000 OrganoPlates® per year. Our propietary technology allows for a unique combination of volume and customization.